Prostate cancer is the leading cancer affecting men in Uganda and a major contributor to cancer-related deaths. Its burden is rising, making awareness and timely screening critical. Understanding the national and international guidelines can help men make informed decisions about their health.
Who should be screened?
Prostate cancer screening is generally not recommended for men under 40 due to its very low prevalence in this age group. Routine screening is also usually not advised for men over 70 unless the decision is made after a careful discussion with a clinician, known as shared decision-making.
The recommended age to start discussions about prostate health depends on risk factors. Average-risk men are encouraged to begin conversations with their doctors around age 45 to 50. Men at higher risk, including those of African descent or with a family history of prostate cancer, should consider starting as early as 40. Ultimately, the decision to screen is individual and should weigh potential benefits against possible harms.
How screening is done
The primary screening tool is the Prostate Specific Antigen (PSA) blood test. While a digital rectal examination (DRE) may be part of clinical evaluation, it is not recommended as a standalone population screening method. Before starting or stopping screening, shared decision-making between the clinician and patient is essential. This includes discussing potential benefits, risks, such as false positives and overdiagnosis, and the patient’s personal values and preferences.
The situation in Uganda
Studies show that prostate cancer screening in Uganda is uncommon, with many men diagnosed at advanced stages (stage III or IV). Although awareness is growing, only a small proportion of men have undergone screening. Screening uptake has been reported as low as five percent to 18.5 percent among men over 50, varying by region. Delayed presentation is common; one study found a median time of 12 months from symptom recognition to diagnosis, with nearly half of patients diagnosed at stage IV.
Barriers include low awareness, myths, such as the belief that ‘all cancers have no cure’, limited availability of services in rural areas, cost, reluctance to undergo testing, and logistical challenges within the health system.
What men can do
Men aged 40 and above, or younger men with risk factors, should discuss prostate health with their doctor, particularly if they have a family history of prostate cancer. Experts at the Uganda Cancer Institute stress that screening is ‘vital for men over 40.’
If screening is undertaken, the PSA test is the starting point. An elevated PSA may lead to further evaluation, including DRE, imaging such as transrectal ultrasound (TRUS), or referral to a specialist. It is important to understand that an elevated PSA does not automatically indicate cancer; benign conditions such as BPH (benign prostatic hyperplasia) can also raise PSA. Screening can lead to false positives, over-diagnosis, and anxiety.
Men should also monitor urinary symptoms such as frequent urination, weak flow, night-time urination, or blood in urine or semen, and seek timely evaluation. Promoting awareness among friends and family and advocating for improved access to screening services, including free or low-cost testing and public education, can help reduce late-stage diagnoses.
Conclusion
Prostate cancer screening in Uganda is guided by clear recommendations, targeting men aged 40-70, using PSA testing, and shared decision-making. Despite the availability of these services, uptake remains low, and many men are diagnosed late.
Engaging with a healthcare provider, understanding personal risk, and taking timely action can lead to earlier diagnosis, better outcomes, and fewer fatalities from prostate cancer.